Genspeed Biotech

Genspeed Biotech is a privately held diagnostics company commercializing a rapid, multiplex immunoassay platform for point-of-care (POC) testing. Its core technology, the GENSPEED xPOC, allows for lab-quality quantification of multiple biomarkers from minimal blood volume, targeting the growing demand for decentralized, personalized diagnostics. The company has transitioned to a revenue-generating stage with a dual business model: selling its own branded tests (e.g., Vitamin D, COVID-19 IgG, TBE IgG) and licensing its IVDR-certified OEM platform to other diagnostic manufacturers. Its strategic focus is on enabling rapid results to drive clinical and consumer health decisions.

GENSPEED xPOC Immuno Multiplex technology for quantitative, simultaneous measurement of up to 8 biomarkers from 20-50 µL of capillary blood in 15-20 minutes. The platform is CE-IVD and IVDR certified for use as an OEM solution.

Genspeed competes in the quantitative point-of-care multiplex segment against companies like Quanterix (SIMOA), LumiraDx, and Abbott (i-STAT). Its key differentiators are its specific focus on capillary blood multiplexing, a commercial IVDR-certified platform for OEMs, and a portfolio of validated commercial tests. Large players have greater sales scale and R&D budgets.